Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Vibha Sharma

Vibha Sharma is a senior reporter covering pharmaceutical and medtech regulatory developments across the globe. She joined Scrip Regulatory Affairs in September 2010 and has since then been at the center of deciding and writing news on important regulatory issues affecting the pharma and medtech sectors and explaining their implications for the industry.

Her fields of interest include the EU Pharmacovigilance legislation and the EU Paediatrics Regulation on which she has written several exclusive articles from various industry conferences. She has also commissioned some pieces of expert analysis on major developments in the pharma and medtech regulatory arenas.

Before joining Informa, she was principal correspondent with India's national newspaper Hindustan Times, where she reported on health and medical issues, besides several other topics. She has also worked with two other Indian national dailies, The Indian Express and The Asian Age.

Advertisement
Set Alert for Articles By Vibha Sharma

Latest From Vibha Sharma

Situation Far From Ideal But EU Network Will Survive Brexit

Brexit undoubtedly will cause some short-term disruption to the EU medicines regulatory network but the network will survive without the UK. That’s according to former European Medicines Agency head Thomas Lönngren. Meanwhile, the timetable for relocating the EMA is likely to be finalized in a few days’ time – as are the criteria for hosting the agency when it moves from London.

Brexit Regulation

UK Election Extends Industry Wait For Accelerated Access Review Response

The UK government’s response to the Accelerated Access Review report is on hold until after the snap general election in June.

Regulation United Kingdom

EMA May Clash With Ethics Committees If It Asks For Earlier Neonatal Trials

As the European Medicines Agency starts to address the findings of a report that questions the wisdom of granting lengthy deferrals for neonatal studies, an industry expert warns that by requiring such studies to be initiated earlier, the agency may come into conflict with ethics committees.

Regulation Clinical Trials

EMA Reviews Experience With Deferring PIPs: Will it Result In Earlier Pediatric Trials?

The European Medicines Agency is examining its current experience with granting deferrals for studies mandated under the EU Paediatric Regulation, and is re-considering when it is most appropriate to grant deferrals for neonatal studies.

Regulation Clinical Trials

Revised EU Guide On Warnings For Certain Excipients Brings Clarity

Changes have been proposed to EU guidance that explains what warnings drug companies should include in their package leaflets and labels for certain excipients.

Regulation Europe

EMA Adopts New Policy on ‘Improprieties’ Despite Lack Of Safety Concerns In 43 Cases To Date

Even though the European Medicines Agency has not found any safety concerns in relation to 43 external complaints of alleged improprieties affecting medicines received since 2013, it has adopted a new policy to deal with such reports in a consistent manner.

Regulation Europe
See All
Advertisement
UsernamePublicRestriction

Register